Cardio.Effect Service

Ncardia’s Cardio.Effect Service provides a cardiac safety assessment of drug candidates over a longer time frame (up to 48 hours). Besides acute drug effects, the assay is capable of revealing chronic cytotoxicity and traffic inhibition of important cardiac ion channels such as hERG. Due to its cost-effectiveness, this service is ideal for screening larger numbers of compounds.

Cardio.Effect is based on label-free impedance recording technology in a standardized in vitro assay system. Parameters analyzed comprise cardiomyocyte beat rate, impedance amplitude and beat rate regularity. In addition, the Cell Index (CI) is a reliable surrogate marker for cell viability.

Service specifications

Cell type

Human iPSC-derived cardiomyocytes

Service type

Impedance functional analysis


96 Well plate

Time points

Cardiotoxicity temporal study (0, 0.5, 1, 2, 8, 24 and 48 hours after compound addition)

Compound concentration*

0.1, 1, 10 µM in medium + 0.1% DMSO (in triplicates)

Positive controls

L-type Ca2+ channel blocker: Nifedipine

Myosin heavy chain inhibitor: Blebbistatin

Vehicle (negative) control

0.1 % DMSO


Impedance amplitude and peak width; beating frequency, induction of arrhythmia and beating arrest; Cell Index (surrogate market for viability)


3 weeks (for up to 9 compounds)


A study protocol will be agreed before study initiation. Analysis data results will be presented in a final study report.

*Suggested concentrations, to be agreed with client